These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24019032)

  • 1. Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution.
    Davidson MH
    Nat Rev Cardiol; 2013 Nov; 10(11):618-9. PubMed ID: 24019032
    [No Abstract]   [Full Text] [Related]  

  • 2. Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors.
    Sahebkar A
    Nat Rev Cardiol; 2014 Jan; 11(1):12. PubMed ID: 24217159
    [No Abstract]   [Full Text] [Related]  

  • 3. Into the future: diversifying lipid management.
    Tonkin AM; Watts GF
    Lancet; 2012 Dec; 380(9858):1971-4. PubMed ID: 23141810
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.
    Giugliano RP; Desai NR; Kohli P; Rogers WJ; Somaratne R; Huang F; Liu T; Mohanavelu S; Hoffman EB; McDonald ST; Abrahamsen TE; Wasserman SM; Scott R; Sabatine MS;
    Lancet; 2012 Dec; 380(9858):2007-17. PubMed ID: 23141813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 inhibition: the next statin?
    Vogel RA
    J Am Coll Cardiol; 2012 Jun; 59(25):2354-5. PubMed ID: 22465426
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.
    Betteridge DJ
    Nat Rev Endocrinol; 2013 Feb; 9(2):76-8. PubMed ID: 23296165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of a monoclonal antibody to PCSK9 on LDL cholesterol].
    Bailén Almorox R
    Rev Clin Esp; 2012 Jul; 212(7):408-9. PubMed ID: 22937541
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    Banerjee Y; Shah K; Al-Rasadi K
    N Engl J Med; 2012 Jun; 366(25):2425-6; author reply 2426. PubMed ID: 22716984
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    Milazzo L; Antinori S
    N Engl J Med; 2012 Jun; 366(25):2425; author reply 2426. PubMed ID: 22716983
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of PCSK9 in familial hypercholesterolaemia.
    Sijbrands EJ
    Lancet; 2012 Jul; 380(9836):6-7. PubMed ID: 22633823
    [No Abstract]   [Full Text] [Related]  

  • 12. [Lipid control in the double pack. Combined drugs to achieve the goal].
    MMW Fortschr Med; 2002 Jun; 144(23):53. PubMed ID: 12119910
    [No Abstract]   [Full Text] [Related]  

  • 13. [In addition to atorvastatin. Innovative antibody lowers LDL around 72%].
    Einecke D
    MMW Fortschr Med; 2012 Apr; 154(7):28. PubMed ID: 22558865
    [No Abstract]   [Full Text] [Related]  

  • 14. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
    Saußele T
    Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ezetimib plus statin combination. A strong duo].
    MMW Fortschr Med; 2002 Nov; 144(48):53. PubMed ID: 12532547
    [No Abstract]   [Full Text] [Related]  

  • 16. Lowering plasma cholesterol by raising LDL receptors--revisited.
    Young SG; Fong LG
    N Engl J Med; 2012 Mar; 366(12):1154-5. PubMed ID: 22435375
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 Apr; 145(16):48-50. PubMed ID: 14606402
    [No Abstract]   [Full Text] [Related]  

  • 19. [Statins plus cholesterol resorption inhibitor. LDL goal values attainable].
    MMW Fortschr Med; 2002 Sep; 144(38):56. PubMed ID: 12395708
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.
    Cicero AF; Tartagni E; Ertek S
    Expert Opin Drug Saf; 2014 Aug; 13(8):1023-30. PubMed ID: 24961142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.